Fumonisin toxicity in a transgenic mouse model lacking the mdr1 a/1b P-glycoprotein genes
Environmental Toxicology and Pharmacology, ISSN: 1382-6689, Vol: 8, Issue: 3, Page: 173-182
2000
- 23Citations
- 9Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations23
- Citation Indexes22
- 22
- CrossRef18
- Policy Citations1
- 1
- Captures9
- Readers9
Article Description
The toxicity of fumonisin B 1 (FB 1 ) was investigated in male mdr 1a/1b double knockout (MDRK) mice, lacking the drug-transporting P-glycoproteins. These transgenic animals are deficient in their blood:brain barrier and accumulate different drugs in brain and other tissues. The MDRK and their wild-type counterparts, FVB mice, were injected subcutaneously with 2.25 mg/kg per day of FB 1 for 5 days and sampled one day after the last treatment in a protocol that has resulted in marked hepatic and renal damage in other strains. FB 1 caused liver enlargement in both FVB and MDRK. Hematological parameters were not affected in either strain. Plasma levels of alanine aminotransferase and aspartate aminotransferase, measures of liver damage, were increased by FB 1 in both FVB and MDRK mice. Histopathological evaluation of liver corroborated this finding. Kidney lesions were induced by FB 1 in both types of mice. Concentrations of free sphingosine and sphinganine increased in liver and kidney of both strains after the FB 1 treatment, although the increase in liver sphingoid bases was half as much in MDRK as compared to FVB. The levels of sphinganine-containing complex sphingolipids were increased in kidney. The levels of sphingosine-containing complex sphingolipids in kidney were unaffected by FB 1 treatment but were significantly lower in control MDRK than in FVB mice. The levels of neurotransmitters and their metabolites were similarly affected in both strains by FB 1, suggesting no influence of disrupted blood:brain barrier on FB 1 –induced neurotoxicity. In both strains, the liver mRNA for tumor necrosis factor α was increased; however, the increase was statistically significant only in FVB. It was apparent that mice deficient in P-glycoprotein do not exhibit greater sensitivity to FB 1, the cellular or brain transport of FB 1 appears to be independent of this multidrug transporting system.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1382668900000387; http://dx.doi.org/10.1016/s1382-6689(00)00038-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0033929114&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/10925070; https://linkinghub.elsevier.com/retrieve/pii/S1382668900000387; http://linkinghub.elsevier.com/retrieve/pii/S1382668900000387; http://api.elsevier.com/content/article/PII:S1382668900000387?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1382668900000387?httpAccept=text/plain; http://dx.doi.org/10.1016/s1382-6689%2800%2900038-7; https://dx.doi.org/10.1016/s1382-6689%2800%2900038-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know